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Abstract
Background: Despite the promise and popularity of advance care planning, there is insufficient evidence that
advance care planning helps patients to meet their end-of-life care preferences, especially in Asian settings. Thus,
the proposed study aims to assess whether patients with advanced heart failure who are receiving advance care
planning have a greater likelihood of receiving end-of-life care consistent with their preferences compared to
patients receiving usual care. Secondary objectives are to compare differences in health care expenditures, quality
of life, anxiety and depression, understanding of own illness, participation in decision-making and concordance
with their caregiver’s preferences for end-of-life care, between patients with advanced heart failure receiving
advance care planning and usual care.
Methods/design: This is a two-arm randomized controlled trial of advance care planning versus usual care
(control) conducted at two institutions in Singapore. Two hundred and eighty-two patients with advanced heart
failure (n = 94 in the advance care planning arm; n = 188 in the control arm receiving usual care) will be recruited
from these centers and followed for 1 year or until they die, whichever is earlier. Additionally, the study will include
up to one caregiver per patient enrolled.
Discussion: If advance care planning is proven to be effective, the results will help to promote its uptake among
health care providers and patients both within Singapore and in other countries.
Trial registration: NCT02299180. Registered on 18 November 2014.
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Background
Worldwide there is an increasing awareness of inad-
equacy in end-of-life (EOL) care provided to patients
with non-cancer-related terminal illnesses, such as ad-
vanced congestive heart failure (CHF) [1]. Data from
several countries shows that despite therapeutic ad-
vances and high health care expenditures [2], patients
with advanced CHF suffer enormously from the physical
and psychological effects of their illness [3–5]. Unlike
many patients with advanced cancer, patients with CHF
typically experience a gradual but non-linear decline in
physical function over many months or years, with occa-
sional periods of exacerbation [6]. The non-linear deteri-
oration in health leads to difficulties in prognostication
and often delayed referral to specialist palliative care ser-
vices. Moreover, there is evidence that patients’ under-
standing of their illness is often poor and
communication with their physician inadequate [7, 8].
These concerns suggest that patients may be receiving
suboptimal EOL care that is not consistent with their
preferences and receiving EOL care that may involve
disproportionately large health care expenditures.
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There is increasing evidence that the presence of ad-
vance directives alone does not help in meeting patient
preferences or in reducing aggressive treatments and
cost of care [9–13]. In contrast, advance care planning
(ACP), one of the most widely discussed and studied of
all EOL conversations, is believed to enable patients to
meet their EOL preferences. This is because ACP is an
ongoing process by which the patient, in consultation
with health care providers and/or family members/care-
givers, makes decisions about their future health care
should they become incapable of participating in medical
treatment decisions. Further, it shifts the focus on EOL
decision-making away from completion of documents
and towards facilitating discussion about values and
preferences regarding treatment and care, and involves
family members in the discussion [9].
Despite the promise and popularity, there has been lit-
tle research evaluating the effectiveness of ACP in meet-
ing patient preferences, especially in Asian settings. One
randomized controlled trial (RCT) of the “Respecting
Choices” model for ACP, among elderly hospitalized pa-
tients in Australia, has reported positive outcomes in en-
abling people to receive EOL treatment as per their
wishes [14]. Another controlled trial, conducted in a
nursing home in the US also found higher compliance
with patients’ wishes among those receiving ACP [15].
An RCT by Kirchhoff et al. [16] among individuals with
CHF or end-stage renal disease failed to show any sig-
nificant difference in the proportion of patients who met
their preferences regarding cardiopulmonary resuscita-
tion (CPR) between the ACP and control arms. Thus,
there has been mixed evidence regarding the effective-
ness of ACP, with none from an Asian setting.
This study aims to fill this gap. It is a two-arm RCT of
patients with advanced CHF to assess the impact of
ACP on health and cost outcomes. The study will be
conducted in Singapore, a rapidly aging country in
Southeast Asia. We will survey the patients in both arms
every 4 months for a period of 1 year or until they die,
whichever is earlier. The primary objective of this trial is
to assess whether patients receiving ACP have a greater
likelihood of receiving EOL care consistent with their
preferences compared to patients receiving usual care.
Secondary objectives are to compare heath care expendi-
tures, quality of life, anxiety and depression, understand-
ing of own illness, participation in decision-making and
concordance with caregiver preferences for EOL care be-
tween patients receiving ACP and usual care. We
hypothesize that patients receiving ACP will be more
likely to receive EOL care consistent with their stated
preferences, and have lower health care expenditures,
better quality of life, lower anxiety and depression, better
understanding of their own illness, greater participation
in decision-making, and greater congruence with




This is a two-arm RCT of ACP versus usual care con-
ducted at two institutions in Singapore –the National
Heart Centre Singapore and Singapore General Hospital
(Department of Internal Medicine). The two hospitals
were chosen because they are the largest centers/hospi-
tals that currently have trained ACP facilitators to de-
liver ACP to patients with advanced CHF. All ACP
facilitators in Singapore are trained based on similar
principles and with similar intensity and methodology.
Therefore, the study results are likely to be generalizable
to patients with advanced CHF who are receiving ACP
at any hospital in Singapore.
Two hundred and eighty-two in-patients with ad-
vanced CHF (n = 94 in the ACP arm; n = 188 in the con-
trol arm receiving usual care) will be recruited from
these centers and followed for 1 year or until they die,
whichever is earlier. Additionally, the study will include
up to one caregiver per patient enrolled.
Randomization will follow a 1:2 (ACP: control arm) ra-
tio. The unequal number of patients in the ACP and
control arms is because it was anticipated that over the
course of the study duration, due to increasing popular-
ity of ACP in Singapore, many patients in the control
arm may decide to take up ACP, thus contaminating the
control arm. If this happens, the larger number of partic-
ipants in the control group is expected to increase the
statistical power for a “per-protocol” analysis [17].
Study population
The study will recruit patients with advanced CHF (New
York Heart Association classes III and IV) while they are
hospitalized, who are 21 years and older and able to give
informed consent. Those with psychiatric or cognitive
disorders, a previously documented ACP or those who
have undergone ACP facilitation will be excluded. The
study protocol has been approved by the Institutional
Review Board at Singhealth.
Intervention
The patient and their family members will be referred to
an ACP facilitator. The ACP facilitator will be certified
in providing ACP. Other than assisting individuals in de-
termining their preferences for future medical care, the
ACP facilitator will provide emotional support to pa-
tients/families with making EOL decisions. Family mem-
bers will be encouraged to be present during the ACP
discussion so that the whole family unit will be able to
explore goals, values and beliefs towards the patient’s
medical care. With family members’ participation, there
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is a greater likelihood that they come to understand and
support the decisions made by the patient during ACP.
Patients will be encouraged to appoint a substitute
health care decision-maker who will make the decisions
on their behalf when they are no longer able to do so.
The ACP document is dated and specifies whether the
patient prefers CPR or not, and whether the patient
wants comfort measures only (medications, oxygen and
other measures may be used for comfort at the place
where the patient lives), limited additional intervention
(may include limited trial of treatment, oral/intravenous
medications, non-invasive ventilation support and trans-
fer to hospital, if needed) or full treatment (may consider
intubation, mechanical ventilation, cardioversion and
transfer to intensive care, if needed) as well as any other
additional care preferences. Preferred place of medical
treatment in the event of deterioration as well as pre-
ferred place of death is also noted in the ACP document.
The names of substitute decision-makers are specified.
A copy of the completed ACP document will be pro-
vided to the patient, substitute health care decision-
makers and the health care team. The ACP document
will be filed onto the front page of the patient’s inpatient
case notes and a copy will be scanned into the patient’s
electronic medical records in the National IT System,
which is shared by all hospitals in Singapore, for easy re-
trieval and viewing in case the patient is admitted to any
hospital in Singapore. This is to ensure that immediate
retrieval of the ACP document is possible when treat-
ment decisions must be made quickly.
Patient preferences among those in the intervention
arm will be reviewed periodically upon readmission or
during the outpatient clinic by the ACP facilitator. If the
patient expresses different preferences towards future
medical care, then the ACP facilitator will conduct a ses-
sion as soon as possible to explore the updated goals for
the patient’s current medical preferences and the exist-
ing ACP document will be voided. If the patient has a
change of mind towards future medical care in between
visits, then the patient will be encouraged to contact the
ACP facilitator in charge via phone of their change in
mind. The ACP facilitator will then arrange for a session
as soon as possible to explore the patient’s wishes and
update the ACP document.
Control arm
The control arm patients will not take part in ACP dis-




The primary outcome to be assessed in the study is the
proportion of patients receiving EOL care consistent with
their stated preferences. Patients’ stated preferences for
CPR, life-prolonging treatments (comfort measures only/
limited intervention/full treatment), place of care and
place of death will be assessed from their last survey or
their ACP document. The actual treatment received by
the patient will be assessed from their medical records
after the patient’s death. If these records are unavailable,
this information will be assessed in post-death interviews
with the patient’s family members/surrogate decision-
maker. Actual place of death will be ascertained from
death certificates and actual place of care from post-death
interviews with the patient’s family members/surrogate
decision-maker. The analysis will only be conducted for
the sub-group of patients who die during the study period.
Secondary outcomes:
1. Heath care expenditures during study duration:
inpatient costs will be assessed through linkages
with hospital billing records
2. Patients’ quality of life: patients’ quality of life will be
measured through Kansas City Cardiomyopathy
Questionnaire (KCCQ). The KCCQ is a 23-item ques-
tionnaire that quantifies physical limitations, symp-
toms, self-efficacy, social interference and quality of
life for patients with CHF [18]. This scale will be ad-
ministered both during baseline and follow-up survey
3. Patients’ anxiety and depression: we will assess
patients’ anxiety and depression through the
Hospital Anxiety and Depression Scale (HADS) [19,
20]. HADS is an extensively used, valid and reliable
scale to measure anxiety and depression among
patients in non-psychiatric hospital clinics. It has
two subscales – an anxiety subscale (HADS-A) and
a depression (HADS-D) subscale, with a total score
ranging from 0 to 21 for each. Internal consistency
(Cronbach’s alpha) for HADS-A varies from .68 to
.93 and for HADS-D from .67 to .90. An optimal
balance of sensitivity and specificity is achieved by a
score of 8 or above on both HADS-A and HADS-D.
The sensitivity and specificity for both HADS-A and
HADS-D is 0.80 [19]. These scales will be adminis-
tered during the baseline interview and during
follow-up surveys with the patient
4. Patients’ understanding of own illness:
understanding of illness will be assessed by asking
patients whether they thought that their current
treatments would help them to live longer (yes/no/
unsure), cure their heart condition (yes/no/unsure)
and relieve their symptoms (yes/no/unsure)
5. Patients’ participation in decision-making: patients’
participation in decision-making will be measured by
the Decisional Conflict Scale [21] administered at
baseline and in follow-up surveys. The Decisional
Conflict Scale measures patient’s state of uncertainty
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about the course of action to take. This state is likely
to occur when making choices involving risk or un-
certainty of outcomes and the need to make trade-
offs in selecting a course of action (e.g., when
making decisions regarding EOL treatment and
care). The scale’s internal consistency ranges from
0.78 to 0.92 and the test-retest reliability coefficient
is .81 [21]. It has also been used and validated
among cancer patients [22]
6. Patient and caregiver congruence in EOL
preferences: for patients whose caregivers also
consent to participate in the survey, we will assess
their preferences for patient’s EOL care – CPR, life-
prolonging treatments and place of death
Recruitment and data collection
A list of patients with heart failure who are admitted at
each center will be sent to the research team daily by
heart failure nurses/research coordinators from these
centers. The research team will then screen the list for
eligibility criteria and approach the patient and family
members for participation in the study; those agreeable
to participate will be administered a written informed
consent form and administered the baseline survey.
Eligible patients who consent to participate in the
RCT and answer the survey questionnaires will be ran-
domized to the ACP and control arms. Participants who
are randomized into the intervention (ACP) arm will
meet with ACP facilitators within 48 hours of consent
for intervention delivery. Patients randomized to the
control arm will not take part in ACP discussions and
documentation, but will continue to receive usual care.
Randomization will be done using block randomization
by generating a random allocation sequence of partici-
pants to the intervention and control arms through a
computerized random number generator. This will be
done by a statistician at the institution. The allocation will
be concealed in sequentially numbered, opaque and sealed
envelopes by the data manager and given to the research
coordinator conducting patient recruitment at the two
centers. Envelopes will be opened sequentially by the re-
search coordinator only after the participant unique ID is
written on the envelope. Randomization sequence will not
be known to the research coordinator, health care pro-
viders (physicians, ACP facilitators, heart failure nurses)
and other researchers involved in the study.
Patients will be followed by the research team for
1 year or until death, whichever is earlier. Further
follow-up may be needed if the targeted number of
deaths in the intervention and control arms is not
reached within the 1-year follow-up period. Patients will
be interviewed first at baseline and then every 4 months.
At the end of the follow-up period, their medical and
billing records will be reviewed to assess the treatment
they received and related costs. All questionnaires for
both patients and caregivers will be administered in their
preferred language from a selection of four: English,
Mandarin, Malay, and Tamil. If the patient dies during
the study, consenting caregivers will be asked to
complete a post-death questionnaire (Fig. 1).
Patient particulars and details of their next follow-up
will be stored on a secure database to be built before the
commencement of the study. This database will send
text reminders to patients and their interviewers before
every follow-up visit. Unique log-in for staff will be re-
quired for access.
Sample size
Similar to a previous RCT, [14] we assumed that the
proportion of patients receiving EOL care consistent
with their stated preferences in the control arm will be
15 % compared to 65 % in the intervention arm. To
achieve 90 % power to detect a difference in outcome
between arms with a certainty of 95 %, we estimated that
we will need 14 deaths in the intervention arm and 28
deaths in the control group. Assuming a mortality of
about 15 % in 1 year, we will require at least 94 patients
in the intervention arm and 188 patients in the control
group. If the total number of deaths in the intervention
and control arms is not reached during the planned 1-
year follow-up period, further follow-ups will be needed.
Proposed statistical analysis
All analysis will be done as per the intention-to-treat
principle. In addition, a “per-protocol” analysis will also
be conducted. For the analysis of primary outcome, we
will use the kappa statistic to assess congruence between
preferred and actual place of death and for each of the
life-sustaining treatments. The chi-square test or Fisher’s
exact test as appropriate will be used for testing the as-
sociation between receiving care consistent with patients
stated preference and the type of intervention. The ana-
lysis will be conducted in the sub-group of patients who
die during the study duration.
For comparing health care expenditures between the
two arms, we will use ordinary least squares regression
to model health care expenditures with the type of inter-
vention as the primary predictor. The model will adjust
for any differences in baseline characteristics between
the two arms and primary diagnosis. If health care ex-
penditure data are not normally distributed, appropriate
transformations or two-part models will be used.
For comparing quality of life, anxiety and depression,
understanding of own illness and participation in
decision-making, we will use separate mixed-effects
models to analyze the changes over time and determine if
change over time differs between the intervention and
control arms. We will adjust for differences in baseline
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characteristics between the intervention and control arms
in the model. Missing observations will be accounted for
under the missing-at-random assumption of the mixed-
effects model. This is a reasonable and common assump-
tion. If the data are not normally distributed, appropriate
transformations will be attempted before resorting to the
use of nonparametric statistical analysis methods. Finally,
the kappa statistic will be used to test the congruence be-
tween the patient’s preference and the caregiver’s prefer-
ence in the analysis of the secondary outcome.
Qualitative in-depth interviews
We will conduct qualitative in-depth interviews with the
health care staff involved in providing ACP and with fam-
ily members/nominated surrogates of deceased patients.
In these in-depth interviews, we will examine their views
and experiences regarding ACP and why they believe ACP
is successful or not in meeting patient preferences for
EOL care. This will enable us to identify the strengths and
limitations of ACP in Singapore and in tailoring the inter-
vention to address limitations and replicate it in other
health care institutions in Singapore and other countries.
Discussion
This study assesses the impact of ACP in meeting prefer-
ences for EOL care among patients with advanced CHF.
Until now, this outcome has been evaluated only in one
RCT by Detering et al. [14]. However, that RCT was con-
ducted among elderly hospitalized patients with varied
diagnoses and not specifically among patients with ad-
vanced CHF [14]. Further, we do not know whether the
beneficial effect of ACP is also applicable to Asian settings
where family caregivers and physicians mostly make deci-
sions for the patient. In addition, the present study will also
assess whether ACP lowers health care expenditures, im-
proves quality of life, decision-making and understanding
of illness. If the study results show that ACP is effective, this
will promote its uptake among health care providers and
patients both within Singapore and in other countries.
Limitations
Attrition may be a problem. We will try to minimize this
through appropriate patient incentives and by scheduling
interviews at times and places convenient for patients. It
is also not possible to execute a double-blinded trial of
ACP given that ACP is provided by a multidisciplinary
team. Unblinded trials may be prone to bias, such as in as-
sessment of primary outcome. We will attempt to reduce
subjectivity in assessment of the outcome by having more
than one senior investigator in the study team to review
the contents of the medical records and to assess compli-
ance with patients’ wishes as stated in the ACP or the
Patients with NYHA Class III or IV heart failure, age 21 
or older, no previous documented ACP, no previous 
ACP facilitation, no cognitive and/or psychiatric 
impairments
Obtain consent
Patient completes patient baseline questionnaire
When applicable, caregiver completes caregiver 
baseline questionnaire
Randomization (n=282)
Intervention arm (ACP, n=94) Control arm (usual care, n=188)
Patient completes questionnaire every 4 months for 
duration of 1 year or until death, whichever is earlier
When applicable, caregiver completes questionnaire 
every 4 months for duration of 1 year or until patient 
death, whichever is earlier
In event of patient death, caregiver completes a post-
death questionnaire
Fig. 1 Study procedures
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survey documents. Contamination of the control arm is
also possible if patients in the control arm seek ACP out-
side of the trial, during the follow-up phase.
Strengths
The multidisciplinary research team brings the experience
required to successfully complete the proposed study. The
intervention to be evaluated (ACP) is one of the most
promising interventions to promote conversations regard-
ing EOL care between providers, patients and family
members. Further, the ACP delivered is a standardized
program developed based on the “Respecting Choices
Program.” The facilitators are well trained and the envir-
onment for program delivery is conducive because of sup-
port from hospital staff, physicians and the government.
Lastly, we will also examine the reasons for success or
failure of the ACP program in meeting the aims through
qualitative in-depth interviews with health care staff and
family members/nominated surrogates of the deceased.
This will enable us to identify the strengths and limita-
tions of ACP. Thus, the study is expected to have large
potential benefit to society and may ultimately lead to
improved clinical approaches to the care of patients with
advanced CHF at the EOL.
Trial status
The trial has been approved and is currently recruiting.
Abbreviations
ACP, advance care planning; CHF, congestive heart failure; CPR,
cardiopulmonary resuscitation; EOL, end-of-life; HADS, Hospital Anxiety and
Depression Scale; KCCQ, Kansas City Cardiomyopathy Questionnaire
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